Market Research on Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Complete report available @ Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 73, 71, 4, 65, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 6, 9 and 1 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AbbVie Inc Acceleron Pharma Inc Adaptimmune Therapeutics Plc Aduro BioTech Inc Advanced Cancer Therapeutics Advenchen Laboratories LLC Affitech A/S Alethia Biotherapeutics Inc Altor BioScience Corp Ambrx Inc Amgen Inc Ampio Pharmaceuticals Inc Apac Biotech Pvt Ltd Apcure SAS APEIRON Biologics AG Aphios Corp Aptevo Therapeutics Inc Aravive Biologics Inc arGEN-X BV Argos Therapeutics Inc ARMO Biosciences Inc ArQule Inc Arrowhead Pharmaceuticals Inc Astellas Pharma Inc AstraZeneca Plc ATLAB Pharma SAS Bayer AG BeiGene Ltd Berg LLC Bio-Cancer Treatment International Ltd Biocad Bionomics Ltd Bionovis SA Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc CASI Pharmaceuticals Inc Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Cellular Biomedicine Group Inc Chipscreen Biosciences Ltd Cleave Biosciences Inc COARE Biotechnology Inc Coherus BioSciences Inc Corcept Therapeutics Inc Corvus Pharmaceuticals Inc Cytune Pharma SAS Daiichi Sankyo Company Ltd Dr. Reddy's Laboratories Ltd Ecrins Therapeutics SAS EirGenix Inc Eisai Co Ltd Eli Lilly and Company Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Gene Techno Science Co Ltd Genor BioPharma Co Ltd GlaxoSmithKline Plc Glycotope GmbH HEC Pharm Co Ltd Hemispherx Biopharma Inc Horizon Pharma Plc Hutchison MediPharma Ltd Immatics Biotechnologies GmbH Immune Design Corp Immunicum AB ImmunoFrontier Inc ImmunoGen Inc Immunomedics Inc Incuron LLC Incyte Corp Innate Immunotherapeutics Ltd Inspyr Therapeutics Inc Intech Biopharm Ltd Johnson & Johnson KAHR medical Ltd Karyopharm Therapeutics Inc KineMed Inc Komipharm International Co Ltd Kyowa Hakko Kirin Co Ltd Lead Discovery Center GmbH Mabion SA MacroGenics Inc MaxiVAX SA MediaPharma srl MedImmune LLC Medivation Inc Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Molecular Partners AG Moleculin Biotech Inc Monopar Therapeutics LLC Mycenax Biotech Inc NanoSmart Pharmaceuticals Inc Nektar Therapeutics NewLink Genetics Corp Novartis AG NovaTarg Therapeutics Inc Omeros Corp OncBioMune Pharmaceuticals Inc Oncobiologics Inc Oncolys BioPharma Inc OncoMax OncoTherapy Science Inc Ono Pharmaceutical Co Ltd Peloton Therapeutics Inc Pfizer Inc Pharma Mar SA Pharmacyclics Inc Pharmicell Co Ltd Pivotal BioSciences Inc Prima BioMed Ltd PsiOxus Therapeutics Ltd Recombio SL Rexahn Pharmaceuticals Inc Richter Gedeon Nyrt Sanofi Selvita SA Sevion Therapeutics Inc Shanghai Henlius Biotech Co Ltd Sillajen Biotherapeutics Sorrento Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Syndax Pharmaceuticals Inc Synthon Holdings BV Taiwan Liposome Company Ltd Takeda Pharmaceutical Company Ltd Tara Immuno-Oncology Therapeutics LLC Taris Biomedical LLC TC BioPharm Ltd Teva Pharmaceutical Industries Ltd Theravectys SA Tocagen Inc TRACON Pharmaceuticals Inc TVAX Biomedical Inc Tyrogenex Inc UroGen Pharmaceuticals Ltd Valeant Pharmaceuticals International Inc Vascular Biogenics Ltd Vault Pharma Inc Vaxeal Holding SA Vyriad Inc X4 Pharmaceuticals Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###